Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 30;34(2):172-179.
doi: 10.31138/mjr.34.2.172. eCollection 2023 Jun.

Prevalence & Impact of COVID-19 in Systemic Sclerosis Patients and Assessment of the Demographic & Clinical Features in Cases Associated with Worse Prognosis: Results of a Single Centre Registry

Hadi Poormoghim  1 , Fatemeh GaffariRad  1 , Shahrzad Rahmani  1 , Negin Mohtasham  1 , Simin Almasi  1 , Ali Sobhani  1 , Maryam Salimi-Beni  1 , Elham Andalib  1 , Parsa Amiri Naeini  1 , Arash Jalali  1
Affiliations

Prevalence & Impact of COVID-19 in Systemic Sclerosis Patients and Assessment of the Demographic & Clinical Features in Cases Associated with Worse Prognosis: Results of a Single Centre Registry

Hadi Poormoghim et al. Mediterr J Rheumatol. .

Abstract

Background: Our knowledge of the COVID-19 infection impact on systemic sclerosis (SSc) is scarce. This study aimed to assess the prevalence of COVID-19 infection and to determine the predictive factors of worse outcomes and death in SSc patients.

Methods: In this cohort study all patients who attended our clinic between 20th February 2020 and 20th May 2021 were followed, and those with a history of COVID-19 infection completed the questionnaire. Results of para-clinical tests were extracted from the SSc database. The outcomes were classified as: alive vs. deceased and, mild vs. worse outcomes. Descriptive statistics and binary logistic regression models were applied.

Results: Of the total 192 SSc patients studied, COVID-19 affected 12.5%; 6% experienced mild disease, 7% were hospitalized and 3% died. The worse outcome was associated with: older age [95%CI: 1.00-1.08], smoking [95%CI: 2.632-33.094], diabetes [95%CI: 1.462-29.654], digital pitting scars (DPS) [95%CI: 1.589-21.409], diffusing capacity of the lungs for carbon monoxide [DLCO<70 [95%CI: 1.078-11.496], left ventricular ejection fraction (LVEF)<50% [95%CI: 1.080-38.651], systolic pulmonary artery pressure (sPAP)>40 mmHg [95%CI: 1.332-17.434], pericardial effusion (PE) [95%CI: 1.778-39.206], and tendon friction rub [95%CI: 1.091-9.387]. Death was associated with male gender [95%CI: 1.54-88.04], hypertension [95%CI: 1.093-2.155], digital ulcers (DU) [95%CI: 0.976-18.34], low forced vital capacity (FVC) [95%CI: 0.03-0.81], and joint flexion contracture (JFC) [95%CI: 1.226-84.402].

Conclusion: Risk factors for the worse outcome in COVID-19 infected SSc patients included, older age, smoking, diabetes, DPS, DLCO<70, LVEF<50%, sPAP>40 mmHg, PE, and TFR. Death was associated with the male gender, hypertension, DU, low FVC, and JFC.

Keywords: COVID-19 impact; COVID-19 prevalence; systemic sclerosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1.
Figure 1.
Forest plot shows univariate analysis of demographic, comorbidity, clinical, and serology features with worse outcome in 24 SSc-patients infected with COVID-19.
Figure 2.
Figure 2.
Forest plot shows univariate analysis of demographic, comorbidity, clinical, and serology features with death outcome in 24 SSc-patients infected with COVID-19.
See this image and copyright information in PMC

References

    1. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed 2020. Mar 19;91(1):157–160. doi: 10.23750/abm.v91i1.9397. - DOI - PMC - PubMed
    1. Toner E, Waldhorn R. What US Hospitals Should Do Now to Prepare for a COVID-19 Pandemic. Baltimore, MD, USA: Johns Hopkins Center for Health Security; 2020.
    1. Izcovich A, Ragusa MA, Tortosa F, Marzio MAL, Agnoletti C, Bengolea A, Ceirano A, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. PLoS One 15(11): e0241955. 10.1371/journal.pone.0241955 - DOI - PMC - PubMed
    1. Ferri C, Giuggioli D, Raimondo V, Dagna L, Riccieri V, Zanatta E, et al. COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study. Lancet Rheumatol 2021. Mar;3(3):e166–e168. 10.1016/S2665-9913(21)00007-2 - DOI - PMC - PubMed
    1. Hoffmann-Vold AM, Brunborg C, Tirelli F, Carreira P, Del Papa N, Mekinian A, et al. The impact and outcome of covid-19 on systemic sclerosis patients from the European Scleroderma trial and research group (EUSTAR). Ann Rheum Dis: first published as 10.1136/annrheumdis-2021-eular.3267 on 19 May 2021. - DOI

LinkOut - more resources